There is some good news to share on the treatment front! Since spring 2025, six provinces in Canada have made publicly funded Ibrutinib + Venetoclax (I+V) combination therapy available for previously untreated CLL patients. These include:
- British Columbia
- New Brunswick
- Newfoundland and Labrador
- Nova Scotia
- Saskatchewan
- Quebec
This therapy is also available to First Nations and Inuit people covered by the Non-Insured Health Benefits Formulary.
For more detail on which patients qualify to receive this treatment, see the Treatment Access tab on CLL Canada’s website.
It is important to note that if you have private health insurance, it’s important to review the specific rules and coverage details of your plan.
Hopefully over the coming months, additional provinces and territories will decide to fund this promising new treatment combination.